Grazoprevir is a drug approved for the treatment of hepatitis C. Grazoprevir is a second-generation hepatitis C virus protease inhibitor acting at the NS3/4a protease targets.
Grazoprevir, a second generation hepatitis C virus protease inhibitor acting at the NS3/4a protease targets, has good activity against a range of hepatitis C virus genotype variants, including some that are resistant to most currently used antiviral medic